Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070)-Reference-Cited by-同舟云学术

Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070)

Published:2007-10 Issue:5 Volume:17 Page:329-331
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Baur Martina,Gneist Margit,Owa Takashi,Dittrich Christian

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference2 articles.

1. Phase I and pharmacokinetic study of E7070, a chloroindolyl–sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors;Dittrich;Clin Cancer Res,2003

2. On behalf of the EORTC New Drug Development and Melanoma Groups. Phase II study of E7070 in patients with metastatic melanoma;Smyth;Ann Oncol,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The inhibitory effect of indisulam-coumarin combined therapy on glioblastoma multiforme;Frontiers in Life Sciences and Related Technologies;2023-12-30

2. ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCN;International Journal of Molecular Sciences;2023-01-13

3. Progress of small molecules for targeted protein degradation: PROTACs and other technologies;Drug Development Research;2023-01-06

4. Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models;Science Advances;2021-11-19

5. Ligandability of E3 Ligases for Targeted Protein Degradation Applications;Biochemistry;2021-09-02